LAEL REYNOLDS: Open Payments
NPI 1689332769 · AMMON, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$941 in 51 payments from 10 companies in 2025. Trend: 2023 $970 · 2024 $1,138 · 2025 $941
Food & beverage: $941
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $247 |
| Neurocrine BioSciences, Inc. | 10 | $170 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $114 |
| Axsome Therapeutics, Inc. | 3 | $94 |
| Otsuka America Pharmaceutical, Inc. | 4 | $91 |
| Alkermes, Inc. | 3 | $79 |
| Teva Pharmaceuticals USA, Inc. | 4 | $62 |
| Lundbeck LLC | 2 | $38 |
| Vanda Pharmaceuticals Inc. | 1 | $31 |
| Indivior Inc. | 1 | $16 |
Products named: VRAYLAR, INGREZZA, CAPLYTA, Auvelity, REXULTI, LYBALVI, ABILIFY ASIMTUFII, AUSTEDO XR.
Industry payments across ID — which companies pay providers there.
